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ABSTRACT
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive myeloid 
neoplasm which shows a high rate of central nervous system (CNS) recurrence and 
overall survival (OS) of <1 year. Despite this, screening for CNS involvement is not 
routinely performed at diagnosis and intrathecal (IT) prophylaxis is not regularly 
administered in BPDCN. Here, we prospectively evaluated 13 consecutive BPDCN 
patients for the presence of CNS involvement by flow cytometry. Despite none of the 
patients presented with neurological symptoms, occult CNS involvement was detected 
in 6/10 cases evaluated at diagnosis and 3/3 studied at relapse/progression. BPDCN 
patients evaluated at diagnosis received IT treatment -either CNS prophylaxis (n = 
4) or active therapy (n = 6)- and all but one remain alive (median follow-up of 20 
months). In contrast, all three patients assessed at relapse/progression died. The 
potential benefit of IT treatment administered early at diagnosis on OS and CNS 
recurrence-free survival of BPDCN was further confirmed in a retrospective cohort 
of another 23 BPDCN patients. Our results show that BPDCN patients studied at 
diagnosis frequently display occult CNS involvement; moreover, they also indicate 




Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN) is a rare disease -i.e.  < 1% acute myeloblastic 
leukemia cases (AML)- with a historically dismal 
prognosis. Despite most BPDCN patients treated with 
different intensive chemotherapy regimens (e.g. CHOP, 
AML-type and acute lymphoblastic leukemia (ALL)-type 
regimens) achieve complete remission (CR), the great 
majority relapse early after CR, with further resistance 
to therapy and a fatal outcome. Of note, a significant 
percentage (≈30%) [1-3] of BPDCN relapses occur in 
the central nervous system (CNS), either as isolated CNS 
relapses or in the context of a systemic relapse. This is in 
line with the relatively high rate (≈10% of cases) [1-6] 
of overt CNS involvement (i.e. confirmed by cytology) 
observed at diagnosis in patients with leukemic variant of 
BPDCN presenting with neurological symptoms.
Although BPDCN prognosis is extremely poor, 
patients treated with ALL-type regimens that include 
CNS prophylaxis [1-3] and/or allogeneic hematopoietic 
stem cell transplantation (AHSCT) [7, 8] appear to show 
a better outcome. Altogether, these findings suggest that 
occult CNS involvement might be already present at 
diagnosis in a significant fraction of BPDCN patients, and 
could contribute to explain the relatively high number of 
CNS recurrences [9].
Here, we prospectively evaluated for the first time 
the presence of CNS involvement by next generation 
flow cytometry (NGF) in 13 consecutive BPDCN patients 
studied at diagnosis (n = 10) or at disease recurrence (n 
= 3). The impact of CNS involvement and CNS-directed 
therapy in patient outcome was further validated in a 
retrospective series of 23 additional BPDCN patients.
RESULTS AND DISCUSSION
At diagnosis, most prospectively analyzed patients 
showed skin lesions (n=10/13; 77%), peripheral blood 
(7/13; 54%) and/or bone marrow (9/13; 69%) involvement 
with normal neurological physical examination (n=13/13; 
100%) and a good performance status (ECOG≤0/1: 
n=12/13; 92%) (Table 1). Despite this, cerebrospinal fluid 
(CSF) samples positive for tumor plasmacytoid dendritic 
cells were found in 6/10 (60%) cases studied at diagnosis 
–median of 11 tumor cells/µl (range: 0.6–47), representing 
82% of the total CSF cellularity (range: 68%-95%)- in 
association with ≥20% bone marrow (BM) infiltration by 
tumor cells (6/6 vs. 1/4 cases, respectively; p=.03). Except 
for the high rate of occult CNS involvement at diagnosis, 
prospectively analyzed here for the first time, the above 
described pattern of extranodal disease involvement has 
been previously reported as typical for BPDCN patients 
[2, 4, 5].
Regarding the 3 patients referred at relapse (5, 7 and 
14 months after diagnosis), none had been screened for 
CNS disease (nor received CNS therapy) at diagnosis; all 3 
had their CSF referred because of the onset of neurological 
symptoms, consisting of seizure in two patients and 
the presence of  symptoms and signs of intracranial 
hypertension together with involvement of cranial nerves 
in the remaining case. They all showed CNS involvement 
by NGF with >50% tumor cells (958, 5 and 46 tumor 
cells/µl, respectively). These results confirm previous 
observations about the relatively high rate of overt CNS 
involvement in BPDCN, particularly at relapse [1-3]; in 
addition, these results also support the notion that many 
BPDCN patients may already have occult CNS disease at 
diagnosis, in the absence of neurological symptoms.
Despite BPDCN patients have been found to show 
already at diagnosis, a rather high rate (≈10%) [1-6] of 
CNS involvement by conventional CSF cytology (e.g. 
similar to ALL patients), they are neither routinely 
screened for CNS involvement, nor receive CNS-directed 
therapy. This is even more striking because CNS relapses 
have been recurrently reported among BPDCN patients 
at relapse at higher frequencies than at diagnosis (≈30%) 
[1-3]. Among other reasons, this might be due to the 
rarity of the disease –and hence the limited experience 
with these patients-, as well as the inclusion of BPDCN 
as a myeloid malignancy in the WHO classification 
[10], where CNS involvement at diagnosis is uncommon 
(<5% of patients) [11] and therefore, systematic CSF 
screening is not performed at diagnosis, in the absence 
of neurological symptoms. Moreover, NGF has not 
been routinely applied for the diagnostic screening of 
CNS involvement in BPDCN patients, despite its higher 
sensitivity over conventional cytology for detecting tumor 
cells on stabilized CSF samples [12, 13], and the fact that 
NGF can detect CNS disease before clinical symptoms 
emerge [14]. 
Of note, follow-up CSF samples obtained after 
triple intrathecal therapy (TIT) showed absence of tumor 
cells in 6/6 CSF+ cases studied at diagnosis, either after 
one -5/6 cases (83%)- or 4 doses of therapy (6/6 cases; 
Table 1). At the moment of closing this study, 5/6 cases 
remained CNS-disease free, in continuous CR; the 
remaining patient (case#4 in Table 1) had an isolated 
CNS relapse 6 months after diagnosis. Upon relapse, the 
patient received intrathecal (IT) chemotherapy, a single 
dose being sufficient to re-induce CR with NGF-negative 
CSF; subsequently, he underwent an AHSCT and remains 
disease-free for >2 years. At the moment of closing this 
study, only 1/10 patients studied at diagnosis had died in 
CR (case #5 in Table 1), the other 9 patients remaining 
alive in CR after a median follow-up of 20 months (range: 
6–48 months). In contrast, those three patients studied at 
disease recurrence suffered disease progression and death, 
despite IT therapy was administered in 2/3 cases (median 
overall survival (OS): 7 months) (Table 1). Overall, these 
findings suggest that BPDCN patients with occult CNS 
involvement at diagnosis might specifically benefit from 
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CNS-directed therapy, particularly if administered (early) 
at diagnosis; in line with this, early administration of 
TIT translated into a significantly better outcome and 
prolonged survival versus cases who did not receive CNS 
prophylaxis/therapy at diagnosis and presented with CNS-
recurrent disease (Figure 1C and 1D). 
In order to further validate our results, a series of 
23 BPDCN patients previously reported in the literature 
[1] -and recruited in an earlier time period-, was 
retrospectively analyzed; of note, no major differences 
were observed between the two cohorts (prospectively 
vs. retrospectively analyzed patients) in terms of disease 
features and outcome (Table 1). Five of these 23 patients 
received IT prophylaxis at diagnosis and 4/23 received 
CNS-directed therapy at relapse/progression (Table 2). 
In this independent validation cohort, patients who did 
receive IT prophylaxis at diagnosis also had prolonged 
CNS recurrence-free survival (CNS-RFS) (p=.06) and 
OS (p=.03) (Figure 1E and 1F). Univariate analysis of 
prognostic factors performed in the whole patient cohort 
(n=36) showed a favorable impact on CNS-RFS and/or 
OS for children (p>.05; p=.03), patients receiving ALL-
type therapy (p=.01; p=.002), AHSCT (p>.05; p=.003) and 
IT prophylaxis/treatment at diagnosis (p=.002; p<.001) 
(Figure 1G and 1H), the later variable emerging as the 
only independent (favorable) prognostic factor for CNS-
RFS (p=.02, hazard ratio [HR]=11.2, 95% confidence 
interval [CI]: 1.4 – 88.8) and OS (p=.001, HR=7.6, 95% 
CI: 2.2 – 25.9).
The high rate of CNS involvement found in our 
study strongly suggests that the CNS could be a persistent 
blast-cell sanctuary in BPDCN patients with leukemic 
Table 1: BPDCN patients included in the prospective cohort (n=13): Disease features at diagnosis and follow-up 
including patient outcome
ECOG: Eastern cooperative oncology group performance status; BM: Bone marrow; PB: Peripheral blood; CSF: 
Cerebrospinal fluid; NGF: Next generation flow cytometry; CC: Conventional cytology; IT: Intrathecal; CNS: Central 
nervous system; AHSCT: Allogeneic hematopoietic stem cell transplantation; M: Male; F: Female; NE: Not evaluated; PD: 
Progressive disease; CYC & PRED: Cyclophosphamide and prednisone; PD: Progressive disease; CR: Complete remission; 
SD: Stable disease; Leptom: Leptomeningeal; TIT: Triple intrathecal therapy (methotrexate cytarabine and hydrocortisone); 
Lip: Liposomal; AraC: cytarabine; HD MTX: High dose methotrexate; NA: Not applicable; NC: No clearance of CSF 
observed; ALL: Acute lymphoblastic leukemia; NR: Not reported; NS: Not statistically significant. #Due to the confirmed 
superiority of NGF versus CC in detecting occult leptomeningeal disease[12], and the limited volume of available CSF 
sample, CC evaluation was not systematically performed in parallel *At any time (diagnosis or follow-up).
Patients were grouped according to their CSF status at diagnosis. Results in the summary groups are expressed as number 
of cases from all cases within the group (for categorical variables) or as median (for continuous  variables) and minimum 
and maximum values.
All the patients had a normal neurological physical examination at diagnosis. 10 were screened for parenchymal involvement 
with a negative result in all these cases. All but case #7 received IT treatment at some point of the disease but none CNS 
radiotherapy. 
"LAL-XXX" (NCT01358201, NCT00853008 and [21]) and Hyper-CVAD are ALL-type protocols, CHOP is a NHL-type 
protocol and FLUGAZA (NCT02319135) is an AML-type protocol. CYC & PRED is a palliative regimen.
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Figure 1: Prognostic impact of (occult) CSF involvement and administration of IT therapy at diagnosis in BPDCN 
patients. CNS-RFS (panels A, C, E and G) and OS (panels B, D, F and H) curves are separately shown for the prospective cohort (panels 
A, B, C and D), the validation cohort (panels E and F) and the combined (prospective and validation) cohort (panels G and H).
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presentation, due to the limited power of cytostatic drugs 
to cross the blood-brain barrier into the CSF and brain 
parenchyma [15]. This reservoir of leukemic cells may 
also contribute to BM/systemic disease recurrence. Longer 
survival rates observed in AHSCT BPDCN patients [7, 
8], irrespective of IT medication administration, might 
be explained by the benefit of the antileukemic effect of 
donor allogeneic cells [16], able to circulate systemically 
and cross the blood-brain barrier. Unfortunately, AHSCT 
is not exempt from relapses (≈1/3 of patients) [7, 8], it 
cannot overcome the poor disease status beyond the 
first CR [7], and toxicity-related mortality is high [17]. 
Additionally, many patients are elderly or unfit subjects to 
undergo such an intensive therapeutic approach. 
Recently, SL-401, a novel targeted therapy directed 
to the interleukin-3 receptor, has shown positive results on 
BPDCN patients with skin confined disease, whereas long-
term benefit has not yet been observed in patients with the 
leukemic variant/phase of the disease [18]. No comparison 
can be established in terms of CNS relapses between both 
approaches (SL-401 vs. IT prophylaxis) since patients 
showing CNS involvement are excluded from the study 
(NCT02113982) and sites of relapse/progression after 
SL-401 administration have not been detailed [18, 19]. 
Nonetheless, evaluation of IT injection of this targeted 
therapy will be of great interest, particularly in CNS 
relapses.  
To the best of our knowledge, this is the first study 
reporting a strikingly high frequency of occult CNS 
involvement at diagnosis in BPDCN patients, and the 
potential benefit of CNS-directed therapy to reverse the 
poor outcome of BPDCN patients,. Indirectly, our results 
also suggest that occult CNS disease might contribute to 
explain the higher frequency of recurrences (e.g. CNS) 
observed in these patients, despite their high CR rates. 
Further prospective studies on larger BPDCN patient 
cohorts studied at diagnosis are necessary to confirm our 
findings.
Table 2: BPDCN patients included in the validation cohort (n=23): Disease features at diagnosis and follow-up 
including patient outcome
BM: Bone marrow; PB: Peripheral blood; CSF: Cerebrospinal fluid; IT: Intrathecal; CNS: Central nervous Sytem; AHSCT: 
Allogeneic hematopoietic stem cell transplantation; M: Male; F: Female; NE: Not evaluated; ALL: Acute Lymphoblastic 
Leukemia; NHL: Non-Hodgkin Lymphoma; AML: Acute Myeloblastic Leukemia; CR: Complete remission; ED: Early 
death; SD: Stable disease; NR: Not reported; TIT: Triple intrathecal therapy (Methotrexate cytarabine and hydrocortisone); 
AraC: Cytarabine; MTX: Metothrexate; Dex: Dexamethasone; PD: Progressive disease; TreatTox: Treatment toxicity; NS: 
Not statistically significant. 
Results in the summary groups are expressed as number of cases from all cases within the group or as median. *At any time 




The study was approved by the Ethics Committee 
of the Cancer Research Center, and performed following 
the Declaration of Helsinki. Each participant gave his/her 
informed consent prior entering the study.
Patients and samples
Forty-one CSF samples from 13 consecutive 
BPDCN patients (11 males and 2 females; median age: 67 
years, range: 11-79 years) were evaluated for the presence 
of CNS involvement by NGF. Cases were evaluated at 
diagnosis (n = 10) or at relapse/progression (n = 3) and 
subsequently, after IT therapy. Diagnosis of BPDCN 
was based on previously reported recommendations 
[10], including expression of markers claimed to be 
mandatory to allocate blast cells to the plasmacytoid 
dendritic cell lineage [20], by either flow cytometry or 
immunohistochemistry of peripheral blood specimens, 
BM samples or cutaneous lesions. The 10 patients studied 
at diagnosis received high-risk ALL-type treatment, based 
on the Spanish PETHEMA protocols (NCT01358201, 
NCT00853008 and [21])(n = 9) or HyperCVAD therapy 
(n = 1), including one dose of TIT as CNS prophylaxis at 
each treatment phase (Table 1). For CSF-positive cases, 
additional IT treatment was given -TIT every 72h (n = 
4) or liposomal cytarabine (50mg) every two weeks (n 
= 2)- until two consecutive CSF-negative samples were 
obtained. In turn, patients with recurrent disease (n = 3) 
received AML-type or NHL-type (CHOP) therapy (Table 
1). 
In order to validate the impact of CNS involvement 
and CNS-directed therapy on patient outcome, an 
independent validation cohort of 23 BPDCN treated 
with ALL- (n = 7), AML- (n = 8) or NHL-type (n = 8) 
therapeutic regimens was retrospectively analyzed [1]. 
The intrathecal treatment administered to these patients is 
detailed in Table 2.
Multiparameter NGF immunophenotypic studies 
were performed on Transfix™-stabilized CSF samples 
(Cytomark, Buckingham, UK) following the EuroFlow 
panels and protocols [12, 22]. Data analysis was performed 
with the Infinicyt software (Cytognos, Salamanca, Spain). 
The lower cut-off for CNS involvement was defined as a 
cluster ≥10 events with the appropriate phenotype, based 
on a 10-parameter tube (≥0.001 cells/µl). 
Statistical analyses
The Mann-Whitney U (for continuous variables) 
and the χ2 tests (for categorical variables) were used 
to determine the statistical significance of differences 
observed between groups (PASW 19 statistical software, 
IBM SPSS Statistics, IBM, Armonk, NY, USA). OS and 
CNS-RFS curves were plotted according to the method 
of Kaplan-Meier and compared using the (one-sided) log-
rank test. Those variables showing prognostic value in the 
univariate analysis were also evaluated by multivariate 
analysis using a Cox stepwise regression model. 
Statistically significance was set at p values  < .05.
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